Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 36M | 35M | 24M | 4M | 228K |
| Gross Profit | 12M | 11M | 8M | 2M | 111K |
| Operating Income | -6M | -6M | -5M | -27M | -2M |
| EBITDA | -6M | -5M | -4M | -26M | -12M |
| Net Income | -6M | -5M | -5M | -27M | -12M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0851
+0.00% today
1Y Change
-68.17%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 166 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sunshine Biopharma, Inc. (SBFMW) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $0.09 and down 68.2% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +4.1%, EPS growth of +80.3%, a dividend yield of 0.0%. What stands out right now is revenue +4.1%, EPS +80.3%, free cash flow +62.9% with operating margin -12.3% and ROIC -18.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Stock Foundry combines SBFMW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SBFMW
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SBFMW Max Drawdown
-85.68%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SBFMW and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$228.4K
-94.7% YoY
FY Net Income
-$12.4M
+53.5% YoY
Free Cash Flow
-$1.8M
+67.1% YoY
Revenue Growth
+4.1%
EPS Growth
+80.3%
Gross Margin
33.5%
Net Margin
-16.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 36M | 35M | 24M | 4M | 228K |
| Gross Profit | 12M | 11M | 8M | 2M | 111K |
| Operating Income | -6M | -6M | -5M | -27M | -2M |
| EBITDA | -6M | -5M | -4M | -26M | -12M |
| Net Income | -6M | -5M | -5M | -27M | -12M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 9M | 10M | 16M | 22M | 2M |
| Total Assets | 3M | 31M | 27M | 30M | 2M |
| Total Liabilities | 597K | 7M | 6M | 8M | 2M |
| Shareholder Equity | 23M | 24M | 21M | 22M | 212K |
| Total Debt | 0 | 952K | 658K | 765K | 2M |
| Net Debt | -9M | -9M | -16M | -21M | -145K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
+65.1% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
2M
+67.1% YoY
Key ratios
Gross Margin
33.5%
Operating Margin
-12.3%
Net Margin
-16.5%
ROE
-25.0%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.